News & Updates

Clinical trials on first-line therapies for advanced or metastatic nonsmall cell lung cancer (NSCLC) from 2010 to 2020 have reported better survival and a steady improvement in quality of life (QoL) among patients, according to the results of a systematic review.

In the subgroup analysis of the phase III FIGARO-DKD trial, the selective nonsteroidal mineralocorticoid receptor antagonist finerenone conferred cardiorenal benefits in Chinese patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). The findings were consistent with that observed in the overall cohort.

Treatment with lotilaner ophthalmic solution 0.25% twice daily for 6 weeks is well tolerated by patients with Demodex blepharitis and has no serious adverse effects compared to a vehicle control, according to a study. Moreover, use of this drop results in clinically meaningful outcomes.

A high incidence of menstrual disorders among women aged ≤54 years has been noted following COVID-19 vaccination, reveals a Netherlands study. Analysis of spontaneous reports supports this observation.

In the treatment of moderate-to-severe benign prostatic hyperplasia (BPH) in Singapore, water vapor thermal therapy (WVTT) is more cost effective than medical management (MM) in the first-line setting based on the common willingness-to-pay threshold of SGD 50,000 per quality-adjusted life-years (QALYs), a study has found.

In the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC) harbouring EGFR mutation, the combination of osimertinib plus pemetrexed and platinum-based chemotherapy outperformed osimertinib alone in terms of extending progression-free survival (PFS), according to the interim results of the phase III FLAURA2 trial presented at WCLC 2023.